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Abstract
Background: UK Biobank is a large prospective cohort study in the UK established by the Medical Research Council
(MRC) and the Wellcome Trust to enable approved researchers to investigate the role of genetic factors, environmental
exposures and lifestyle in the causes of major diseases of late and middle age. A wide range of phenotypic data has
been collected at recruitment and has recently been enhanced by the UK Biobank Genotyping Project. All UK Biobank
participants (500,000) have been genotyped on either the UK Biobank Axiom® Array or the Affymetrix UK
BiLEVE Axiom® Array and the workflow for preparing samples for genotyping is described. The genetic data is hoped
to provide further insight into the genetics of disease. All data, including the genetic data, is available for access to
approved researchers.
Data for two methods of DNA quantification (ultraviolet-visible spectroscopy [UV/Vis]) measured on the Trinean
DropSense™ 96 and PicoGreen®) were compared by two laboratories (UK Biobank and Affymetrix).
Results: The sample processing workflow established at UK Biobank, for genotyping on the custom Affymetrix Axiom®
array, resulted in high quality DNA (average DNA concentration 38.13 ng/μL, average 260/280 absorbance 1.91). The
DNA generated high quality genotype data (average call rate 99.48% and pass rate 99.45%). The DNA concentration
measured on the Trinean DropSense™ 96 at UK Biobank correlated well with DNA concentration measured by
PicoGreen® at Affymetrix (r = 0.85).
Conclusions: The UK Biobank Genotyping Project demonstrated that the high throughput DNA extraction protocol
described generates high quality DNA suitable for genotyping on the Affymetrix Axiom array. The correlation between
DNA concentration derived from UV/Vis and PicoGreen® quantification methods suggests, in large-scale genetic studies
involving two laboratories, it may be possible to remove the DNA quantification step in one laboratory without affecting
downstream analyses. This would result in reductions in cost and time to complete the project, allowing generation of
genetic data faster and cheaper.
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Background
UK Biobank is a resource containing samples and a wide
range of data on 500,000 UK participants. The resource is
available for approved researchers to apply to use for the
purposes of ‘improving health of future generations’ [1–5].
An enhancement project was initiated in 2013 which
aimed to genotype the entire UK Biobank cohort using a
high density array and subsequent imputation. The
majority of participants (~440,000) were genotyped on
the UK Biobank Axiom® Array [6], with 50,000 partici-
pants genotyped on the Affymetrix UK BiLEVE Axiom®
Array [7], which has > 95% content overlap with the UK
Biobank Axiom® Array.
A bespoke sample processing workflow was designed
to ensure the ~500,000 samples could be processed to a
high quality within 18 months. The pipeline involved
three main stages (and three collaborating entities);
preparation of the DNA was performed at UK Biobank,
genotyping at Affymetrix and quality control (QC) of the
data at the Wellcome Trust Centre for Human Genetics
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(WTCHG). The Clinical Trial Service Unit (CTSU) at
the University of Oxford is responsible for the storage
and distribution of the genotype data (and all other UK
Biobank data) to approved researchers.
It is well reported that the concentration obtained
from DNA quantification can differ significantly
dependent upon the DNA quantification method used,
DNA extraction methodology and laboratory [8–11].
Since DNA was extracted at UK Biobank and genotyped
at Affymetrix (following normalisation), both laborator-
ies included a method to quantify the DNA for QC
purposes. This is typical of assays where the DNA
sample is not extracted in-house.
UK Biobank used the Trinean DropSense™ 96 droplet
reader in combination with DropPlate-S (a UV/Vis-based
plate method) and Affymetrix used PicoGreen® (a fluores-
cent dye that intercalates with DNA). This project
provided a unique opportunity to compare two commonly
used DNA quantification methods across a large sample
number. A comparison of these two DNA quantification
methods across two laboratories is presented.
Methods
Methods below describe the DNA extraction/genotyping
workflow for the ~440,000 UK Biobank samples run on
the UK Biobank Axiom® Array. Further detail on the
50,000 UK Biobank samples run on the UK BiLEVE
Axiom® Array is available elsewhere [7].
UK Biobank
Selection of source sample for DNA extraction
UK Biobank participants provide a wide range of bio-
logical samples [4, 5] that are aliquotted into 850 μL, 2D
bar-coded micro tubes prior to storage. The buffy coat
aliquot, derived from 10 ml of whole blood collected
into an ethylenediaminetetraacetic acid (EDTA) vacutai-
ner, was selected for DNA extraction as it was available
for the majority of participants and was expected to yield
the required 10 ng/μL concentration required for geno-
typing. Saliva was considered but due to the lower
number of participants providing this sample type to the
UK Biobank study, this was not used.
During retrieval of buffy coat samples for DNA extrac-
tion it was important to maximise the picking speed
whilst avoiding clustering of participants by time or date
of collection, collection centre, geography (UK Biobank
recruited from 22 assessment centres across the UK), or
any participant phenotype (typically only 2 assessment
centres were represented on each stored plate). An
algorithm was developed to pick the samples in a way
that increased the number of assessment centres per
plate to reduce potential systematic bias from the way
the samples were originally collected and processed that
could affect downstream genotyping.
DNA extraction
A custom DNA extraction system was developed by the
Tecan Integration Group (TIG) [12] to enable DNA ex-
traction and quantification in a single process (Fig. 1).
DNA was extracted from 850 μL of buffy coat using a
cartridge-based, magnetic bead extraction methodology
(Maxwell® 16 Blood DNA Purification Kit, Promega,
AS1010X and Maxwell® 16 Research Instrument [Promega,
AS200-HS]).
DNA extraction occurs within the pre-filled cartridge







Fig. 1 UK Biobank DNA Extraction System. This system comprises 1) Ziath® DataPaq High Speed Single Rack Scanner ZTS-A6 for sample tracking, 2)
two modified hemi-skinned Promega Maxwell® 16 instruments for DNA extraction, 3) Trinean DropSense™ 96 for DNA quantification, 4) Brooks Tube
Auditor™ for volume measurement and 5) Liconic STX44 Automated Incubator to keep DNA at 4 °C after extraction
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containing lysis buffer, MagneSil™ Paramagnetic Particles
(PMPs) and wash buffers. Briefly, DNA is moved
between wells by the PMPs and the application of a
magnetic force to disposable plungers. Cells are lysed by
a guanidine-based lysis buffer alongside mechanical lysis
from the disposable plungers. DNA adsorbed by silica
coated magnetic beads is moved through a series of
wash wells by a plunger. Salts from lysis and other
impurities that may inhibit downstream processing (e.g.
haem, proteins etc.) are removed during the washing.
Once purified, DNA is eluted from the beads in Tris-
EDTA-based lysis buffer, is assisted by heating at 56 °C.
To maximise the DNA yield and purity from the
source material (standard protocol extracts from 250 μL
buffy coat), the lysis buffer (Promega, A826E) was
increased by 600 μL, the wash buffer (Promega,
MD1412) by 1 mL in two wash wells and the cycle
through the cartridge was repeated a further two times.
Following extraction, the DNA was aliquotted across
three tubes; one for primary storage at UK Biobank
(425 μL), one for back-up storage at UK Biobank
back-up centre (425 μL) and one for genotyping (50 μL).
The primary aliquot was quantified on the Trinean
DropSense™ 96.
The quality metrics for a 96-well plate to automatically
proceed to genotyping on the Axiom® array was 80% of the
plate must have a DNA concentration > 10 ng/μL. Prior to
shipping a plate for genotyping, the measured DNA con-
centration and quality (by absorbance at 260/280) of the
stock DNA (sibling to the DNA shipped for genotyping)
were assessed from the concentration obtained from the
Trinean DropSense™ 96. Results from QC checks were
entered into the UK Biobank Laboratory Information
Management System (LIMS) and are a data field that can
be requested by researchers.
Shipment
Following DNA extraction and quantification, DNA was
stored at −80 °C. Plates were sent for genotyping to the
Affymetrix Research Services Lab, Santa Clara, CA, USA
(ARSL) approximately weekly. Plates were shipped on dry
ice and accompanied by an electronic sample manifest
containing an anonymised participant identifier plus the
gender, ethnicity and geographical location of the partici-
pant to which the sample pertains (latter for QC purposes).
Pre-genotyping at affymetrix
Genotyping was performed at the ARSL as per the Man-
ufacturer’s Instructions [13] using the UK Biobank
Axiom® Array or UK BiLEVE Axiom® Array.
In summary, samples were thawed and homogenised
(incubated at 37 °C for 2 h) prior to PicoGreen® quantifi-
cation to establish the volume of DNA required for
normalisation to a concentration of 10 ng/μL. Plates
where < 80% of samples had a concentration of > 10 ng/μL
required authorisation before proceeding to genotyping.
After normalisation, two controls were added to the plate
and samples entered the Axiom® assay workflow [14].
Samples failing initial QC (<95% of markers measured
could be confidently genotyped [call rate]) were re-pro-
cessed. If samples failed re-processing a second sample
from the participant was extracted, where available.
Data analysis was performed as per Manufacturer’s
Guidelines [15]. Any deviations from standard protocol
are documented in [14].
Data QC at WTCHG
QC procedures applied to the UK Biobank genotyped data
are described in [16]. Upon completion of QC, data is
passed to UK Biobank for release to approved researchers.
Results and discussion
The sample processing workflow described aimed to
generate high quality genotypes from as many UK
Biobank participants as possible. At UK Biobank, it was
important to design a workflow that generated high
quality DNA for genotyping on the Axiom® Array (and
use in future downstream applications), whilst maintain-
ing a high throughput so data were available within a
short timeframe. Results are presented for 484,325
samples. Approximately 1% of samples (5016 samples)
were excluded from the analysis because DNA quantifi-
cation data was not available from both Trinean and
PicoGreen quantification.
Success of picking algorithm
The picking algorithm was designed to prevent cluster-
ing of phenotypes (specifically participant assessment
centre). The success of the algorithm was assessed by
selecting 14 plates picked consecutively at the start, mid-
dle and end of the project and counting the number of
assessment centres represented on each plate. Of the 42
plates checked, each plate contained samples from par-
ticipants from at least five assessment centres (Fig. 2).
This demonstrates the picking algorithm was successful
in avoiding clustering of samples by assessment centre
and reducing sample bias on the genotyping plate.
Success of DNA extraction—DNA quantity and quality
assessment at UK Biobank
The novel methodology to extract DNA from 850 μL
of buffy coat was assessed via the DNA concentration
and 260/280, using the Trinean DropSense™ 96 (a
UV/Vis, plate-based DNA quantification system). The
average DNA concentration was 38.13 ng/μL (0.02 to
634.99 ng/μL) and average 260/280 was 1.91 (distri-
bution shown in Fig. 3). The results from quantifica-
tion at UK Biobank indicated the DNA extraction
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Fig. 2 Assessment centres per picked plate. Number of assessments centres per picked plate from three sets of 14 plates from time-points during
picking (start, middle and end)
Fig. 3 DNA quality assessed by 260/280. Spread of 260/280 values across 481,772 DNA samples (results from 2553 samples outside 1.5–2.5 not displayed)
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protocol generated good quality DNA. From DNA
quantification performed at UK Biobank, 1.31% of
samples fell outside the required 10 ng/μL threshold
for automatic pass into the genotyping process.
DNA quantification—comparison of methods
This project provided a unique opportunity to compare
two methods of DNA quantification across a large num-
ber of samples. DNA concentration measured via the
UV/Vis on the Trinean DropSense™ 96 during DNA
extraction at UK Biobank were exported alongside the
PicoGreen® derived concentrations included in the
summary metrics from Affymetrix for each sample from
the UK Biobank LIMS.
Out of the 484,325 samples where data were available
from both quantification methods, the average DNA
concentration measured using the Trinean DropSense™
96 was 38.13 ng/μL (0.02 to 634.99 ng/μl) and via
PicoGreen® was 37.13 ng/μL (0.01 to 730.52 ng/μL; Fig. 4).
Correlation of the two methods was assessed between
the DNA concentration obtained from Trinean Drop-
Sense™ 96 and PicoGreen® quantification methods from
482,638 samples (r = 0.85; Fig. 5; Additional file 1). Some
samples were excluded from the analysis (1687 samples;
0.3%) as there was > 60 ng/μL difference between the
DNA concentration measured by UV/Vis and PicoGreen
quantification methods. This difference in a small
number of samples can be explained by the lack of
homogeneity in some of the DNA samples. The DNA
samples were quantified by UV/Vis immediately after
extraction; it is expected that the DNA is largely
homogenous at this stage as it has recently been eluted
using a combination of mechanical mixing with a
plunger and heat (with the exception of highly viscous
samples). Conversely, PicoGreen® quantification was
performed after storage at −80 °C, shipping on dry ice
and homogenisation by heating. It is possible that a
small number of viscous samples were heterogeneous
during one or both of the DNA quantifications result-
ing in large differences in the measured DNA concen-
trations [17].
Additionally, there were a small number of samples
where one method quantified the DNA near 0 ng/μL and
the other method quantified DNA> 10 ng/μL (87 samples
were quantified as < 2 ng/μL via UV/Vis and > 10 ng/μL via
PicoGreen® and 233 samples were quantified as < 2 ng/μL
via PicoGreen® and > 10 ng/μL via UV/Vis [Additional file
2]). The most likely explanation for the difference would be
failure to transfer DNA to the quantification plate in one of
the quantification methods during automation.
The correlation demonstrates that whilst others
have observed differences between DNA concentra-
tion methodologies [10, 11], the preparation of DNA
as described in this paper yields similar DNA concen-
trations whether measured using a UV/Vis method
(on the Trinean DropSense™ 96) or via PicoGreen®.
The findings from this comparison may assist other
laboratories when considering the sample workflow
Fig. 4 DNA concentration measured by UV/Vis (Trinean) and PicoGreen®. Spread of DNA concentration in 484,325 samples quantified using
Trinean DropSense™ 96 and PicoGreen®
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and whether repeat DNA quantifications of the same
sample are required.
Success of genotyping on axiom® array
Results from DNA concentration checks at UK Bio-
bank indicated that the majority of samples would
meet the requirements for genotyping of DNA con-
centration > 10 ng/μL and 260/280 > 1.8 (98.7% of
samples > 10 ng/μL, 84.3% 260/280 > 1.8). Results from
genotyping (after QC by Affymetrix, prior to WTCHG
QC) for 484,325 samples (average call rate 99.48%
and pass rate 99.45%) demonstrate the DNA gener-
ated from the workflow described is of high quality
and is suitable for downstream genetic analysis;
Axiom genotyping in this case.
The average DNA concentration of the 2675 failed
samples was 36.54 ng/μL (UV/Vis) and 37.15 ng/μL (Pico-
Green®) compared with 38.14 ng/μL and 34.71 ng/μL
(UV/Vis and PicoGreen®, respectively) for samples that
passed. The average 260/280 of failed samples was 1.93
and 1.91 for samples that passed. DNA concentration
metrics from pass and fail samples do not demonstrate
that DNA quantity or quality was not responsible for the
small percentage of failures at the genotyping step.
Conclusions
The UK Biobank Genotyping project was established to
generate genotype data from as many of the 500,000
participants as possible. Data from 150,000 participants
is already available to approved UK Biobank researchers
and will be followed in 2016 by the data from the
remaining participants upon completion of QC and
imputation by WTCHG.
The sample processing workflow described has gener-
ated high quality DNA for the UK Biobank Genotyping
Project and for use in future UK Biobank projects. The
comparison between DNA quantification has demon-
strated Trinean DropSense™ 96 quantification performed
at UK Biobank and PicoGreen® performed at Affymetrix
generates similar results (r = 0.85) which may be
improved further by thorough optimisation of the DNA
homogenisation protocol following thawing. The correl-
ation between DNA concentration derived from UV/Vis
and PicoGreen® quantification methods in this workflow
suggests, in large-scale genetic studies involving two or
more laboratories, it may be possible to remove repeat
DNA quantification steps without affecting downstream
analyses. It is recommended that during the early phases
of a project, the correlation between quantification
methods employed in each laboratory is assessed with
the aim of removing one of the quantification measures
if the correlation is good. Removing a quantification step
in the workflow would lead to increased throughput, a
decrease in consumable costs and a reduction in staff re-
quired which would ultimately allow for generation of
genetic data faster and cheaper.
Fig. 5 Correlation between UV/Vis (Trinean) and PicoGreen® methods of DNA quantification. Correlation between DNA concentration measured
via Trinean DropSense™ 96 and PicoGreen® quantification methods in 482,638 samples (r = 0.85)
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Additional files
Additional file 1: Correlation between UV/Vis (Trinean) and PicoGreen®
methods of DNA quantification (r = 0.85). Solid line r = 1; dashed
line = correlation UV/Vis and PicoGreen® quantification methods
across 482,638 samples (r = 0.85). (PDF 1692 kb)
Additional file 2: Correlation between UV/Vis (Trinean) and PicoGreen®
methods of DNA quantification for DNA concentration < 60 ng/μL.
Correlation plot showing all data points (442,859 samples) where DNA
concentration measured via UV/Vis is < 60 ng/μL. Samples quantified via
one method < 2 ng/ μL and with another method > 10 ng/μL are
highlighted with a black cross. (PDF 166 kb)
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